Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer

Restricted access

Jonathan Loree, MD, is a research fellow at The University of Texas MD Anderson Cancer Center, where his research interests include tumor heterogeneity and biomarkers in colorectal cancer. He completed his medical degree and internal medicine training at the University of Alberta, after which he completed a medical oncology fellowship at the British Columbia Cancer Agency. He is the recipient of a J. Edward Mahoney ASCO Young Investigator Award, a Canadian Association of Medical Oncologists Fellowship Award, and a Royal College of Physicians and Surgeons of Canada Detweiler Travelling Fellowship, and is a member of the University of British Columbia Clinician Investigator Program. He is currently enrolled in a Master's degree program from MD Anderson UTHealth GSBS during his research fellowship at MD Anderson.

The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.

Scott Kopetz, MD, PhD, is an Associate Professor and the Deputy Chair of Translational Research for the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. He graduated summa cum laude from Vanderbilt University with a bachelor's degree in biomedical engineering/electrical and received his medical degree from Johns Hopkins School of Medicine. He obtained his residency training in internal medicine at Duke University Medical Center, followed by a medical oncology fellowship and PhD at MD Anderson Cancer Center. He has authored more than 100 peer-reviewed articles, is a senior editor for Clinical Cancer Research, and is an editorial board member on Journal of Clinical Oncology and JNCI. He is vice-chair for colon cancer research in the NSABP/RTOG cooperative group, and a member of the NIH Gastrointestinal Oncology Steering Committee. He is the principal investigator for several phase I and II clinical trials, including of Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) study, a novel biomarker enrichment program for colorectal cancer. His research interests include the biology of the refractory colorectal cancer and the development of novel therapeutics for molecularly distinct subsets of colorectal cancer patients.

  • 1.

    Sepulveda AR, Hamilton SR, Allegra CJ. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology [published online ahead of print February 6, 2017]. J Clin Oncol, doi: 10.1200/JCO.2016.71.9807.

    • Search Google Scholar
    • Export Citation
  • 2.

    Peeters M, Kafatos G, Taylor A. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials. Eur J Cancer 2015;51:17041713.

    • Search Google Scholar
    • Export Citation
  • 3.

    Douillard JY, Oliner KS, Siena S. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:10231034.

  • 4.

    Forbes SA, Beare D, Gunasekaran P. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43:D805811.

    • Search Google Scholar
    • Export Citation
  • 5.

    Sherman RE, Andersen SA, Dal Pan GJ. Real-world evidence—what is it and what can it tell us? N Engl J Med 2016;375:22932297.

  • 6.

    Morelli MP, Overman MJ, Dasari A. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 2015;26:731736.

    • Search Google Scholar
    • Export Citation
  • 7.

    Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012;30:741747.

    • Search Google Scholar
    • Export Citation
  • 8.

    Baas JM, Krens LL, Guchelaar HJ. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 2011;16:12391249.

    • Search Google Scholar
    • Export Citation
  • 9.

    Van Cutsem E, Lenz HJ, Kohne CH. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692700.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 159 108 3
PDF Downloads 41 38 3
EPUB Downloads 0 0 0